Related Experiment Video
Updated: Jul 5, 2025
Author Spotlight: Advancements in Nanoparticle Technology for Drug Delivery and Immunotherapy
Published on: November 10, 2023
Exploring nanocarriers as innovative materials for advanced drug delivery strategies in onco-immunotherapies
Pratiksha Tiwari1, Ravi Prakash Shukla2, Krishna Yadav2
1Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute Lucknow, India; Jawaharlal Nehru University, New Delhi, India.
Abstract:
In recent years, Onco-immunotherapies (OIMTs) have been shown to be a potential therapy option for cancer. Several immunotherapies have received regulatory approval, while many others are now undergoing clinical testing or are in the early stages of development. Despite this progress, a large number of challenges to the broad use of immunotherapies to treat cancer persists. To make immunotherapy more useful as a treatment while reducing its potentially harmful side effects, we need to know more about how to improve response rates to different types of immunotherapies. Nanocarriers (NCs) have the potential to harness immunotherapies efficiently, enhance the efficiency of these treatments, and reduce the severe adverse reactions that are associated with them. This article discusses the necessity to incorporate nanomedicines in OIMTs and the challenges we confront with current anti-OIMT approaches. In addition, it examines the most important considerations for building nanomedicines for OIMT, which may improve upon current immunotherapy methods. Finally, it highlights the applications and future scenarios of using nanotechnology.
Insights
Onco-immunotherapies (OIMTs) show promise for cancer treatment, but challenges remain. Nanocarriers (NCs) offer a way to improve OIMT efficacy and reduce side effects, paving the way for better cancer therapies.
Area of Science:
- Oncology
- Immunology
- Nanotechnology
- Materials Science
Background:
- Onco-immunotherapies (OIMTs) represent a significant advancement in cancer treatment, with several therapies approved and many more in clinical development.
- Despite progress, challenges hinder the widespread application of OIMTs, necessitating strategies to improve response rates and mitigate adverse effects.
Purpose of the Study:
- To discuss the integration of nanomedicines into OIMTs to enhance treatment efficacy and minimize side effects.
- To examine the challenges associated with current anti-OIMT strategies.
- To explore key considerations for designing nanomedicines for OIMTs and highlight future applications of nanotechnology in this field.
Main Methods:
- Review of current literature on OIMTs and nanocarrier applications in cancer therapy.
- Analysis of challenges in current immunotherapy approaches.
- Discussion of design principles for nanomedicines in OIMTs.
Main Results:
- Nanocarriers (NCs) demonstrate potential for efficient delivery and enhanced efficacy of immunotherapies.
- NCs can significantly reduce the severe adverse reactions associated with OIMTs.
- Strategic incorporation of nanomedicines can overcome limitations of current anti-cancer immunotherapy methods.
Conclusions:
- Nanomedicine integration is crucial for advancing OIMTs, improving patient outcomes, and broadening therapeutic applications.
- Further research into nanomedicine design and application is essential for realizing the full potential of OIMTs in oncology.
- Nanotechnology holds significant promise for the future of cancer immunotherapy, offering innovative solutions to existing challenges.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...